| Literature DB >> 33186461 |
Tiziana Bruno1, Francesca De Nicola1, Giacomo Corleone1, Valeria Catena1, Frauke Goeman1, Matteo Pallocca1, Cristina Sorino1, Gianluca Bossi2, Bruno Amadio1, Giovanni Cigliana3, Maria Rosaria Ricciardi4, Maria Teresa Petrucci5, Enrico Pierluigi Spugnini1, Alfonso Baldi6, Mario Cioce2, Giancarlo Cortese1, Elisabetta Mattei7, Roberta Merola3, Umberto Gianelli8, Luca Baldini8, Francesco Pisani9, Svitlana Gumenyuk9, Andrea Mengarelli9, Katja Höpker10, Thomas Benzing10,11,12, Bruno Vincenzi13, Aristide Floridi1, Claudio Passananti14, Giovanni Blandino2, Simona Iezzi1, Maurizio Fanciulli1.
Abstract
Multiple myeloma (MM) is a hematologic malignancy produced by a clonal expansion of plasma cells and characterized by abnormal production and secretion of monoclonal antibodies. This pathology exhibits an enormous heterogeneity resulting not only from genetic alterations but also from several epigenetic dysregulations. Here we provide evidence that Che-1/AATF (Che-1), an interactor of RNA polymerase II, promotes MM proliferation by affecting chromatin structure and sustaining global gene expression. We found that Che-1 depletion leads to a reduction of "active chromatin" by inducing a global decrease of histone acetylation. In this context, Che-1 directly interacts with histones and displaces histone deacetylase class I members from them. Strikingly, transgenic mice expressing human Che-1 in plasma cells develop MM with clinical features resembling those observed in the human disease. Finally, Che-1 downregulation decreases BRD4 chromatin accumulation to further sensitize MM cells to bromodomain and external domain inhibitors. These findings identify Che-1 as a promising target for MM therapy, alone or in combination with bromodomain and external domain inhibitors.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33186461 PMCID: PMC7686885 DOI: 10.1182/bloodadvances.2020002566
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529